Boston Partners reduced its stake in Solventum Corporation (NYSE:SOLV – Free Report) by 11.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 3,577,916 shares of the company’s stock after selling 460,047 shares during the quarter. Boston Partners’ holdings in Solventum were worth $315,383,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC bought a new stake in Solventum in the third quarter worth about $29,000. JNBA Financial Advisors boosted its stake in Solventum by 71.9% in the second quarter. JNBA Financial Advisors now owns 507 shares of the company’s stock valued at $39,000 after acquiring an additional 212 shares during the last quarter. Ameritas Advisory Services LLC bought a new position in shares of Solventum during the 2nd quarter valued at approximately $47,000. Ancora Advisors LLC bought a new position in shares of Solventum during the 2nd quarter valued at approximately $56,000. Finally, Western Wealth Management LLC bought a new position in shares of Solventum during the 1st quarter valued at approximately $58,000.
Solventum Stock Up 0.4%
SOLV opened at $86.43 on Thursday. The company has a 50 day moving average of $87.32 and a 200 day moving average of $79.11. The company has a market cap of $14.67 billion, a PE ratio of 12.21, a price-to-earnings-growth ratio of 1.22 and a beta of 0.69. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $94.16. The company has a current ratio of 1.03, a quick ratio of 0.72 and a debt-to-equity ratio of 0.99.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 12th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up from $105.00) on shares of Solventum in a research note on Friday, November 6th. BTIG Research reissued a “buy” rating on shares of Solventum in a report on Friday, November 6th. Stifel Nicolaus raised their target price on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Wells Fargo & Company boosted their target price on Solventum from $89.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Solventum has a consensus rating of “Moderate Buy” and an average target price of $90.27.
Get Our Latest Report on Solventum
About Solventum
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Featured Articles
- Five stocks we like better than Solventum
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
